Lyka Labs (BOM:500259) Gross-Profit-to-Asset % : 40.31% (As of Mar. 2024)

View and export this data going back to 1992. Start your Free Trial

What is Lyka Labs Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Lyka Labs's annualized Gross Profit for the quarter that ended in Mar. 2024 was ₹632 Mil. Lyka Labs's average Total Assets over the quarter that ended in Mar. 2024 was ₹1,567 Mil. Therefore, Lyka Labs's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was 40.31%.

Lyka Labs Gross-Profit-to-Asset % Historical Data

The historical data trend for Lyka Labs's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lyka Labs Gross-Profit-to-Asset % Chart

Lyka Labs Annual Data

Trend

Jun14

Jun15

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

9.43

14.83

69.37

32.94

43.05

Lyka Labs Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															37.75	35.29	42.93	55.01	40.31

Competitive Comparison of Lyka Labs's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Lyka Labs's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lyka Labs's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lyka Labs's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Lyka Labs's Gross-Profit-to-Asset % falls into.

Lyka Labs Gross-Profit-to-Asset % Calculation

Lyka Labs's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Mar. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Mar. 2024 )	/	( (Total Assets (A: Mar. 2023 )	+	Total Assets (A: Mar. 2024 ))	/ count )
	=	663.429	/	( (1515.228	+	1567.243)	/ 2 )
	=	663.429	/	1541.2355
	=	43.05 %

Lyka Labs's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	631.796	/	( (0	+	1567.243)	/ 1 )
	=	631.796	/	1567.243
	=	40.31 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Lyka Labs Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Lyka Labs's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Lyka Labs (BOM:500259) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lyka Labs Ltd (BOM:500259) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

LYKALABS:India

Address

30, Forjett Street, Near Bhatia Hospital, Ground floor, Spencer Building (Block B & C), Grant Road (West), Mumbai, MH, IND, 400036

Website

http://www.lykalabs.com

Lyka Labs Ltd is an Indian biotechnology company. It mainly engages in the development of specialized formulations. The Company is engaged in only one segment viz. pharmaceuticals. The Company has presence in Domestic as well as International markets. The commercialized formulations of the company consist of hair care, anti-aging, acne management, skin lightening, face washes, sunscreens, facial scrubs, and others. It has developed a varied drug delivery system for topical steroids, painkillers, anti-fungal, and other emollients as well as liquid injectables, lyophilized injectables in the anti-bacterial, antifungal segment. The company also manufactures proton pump inhibitors, antibiotics, antifungals, steroids, etc. The majority of the company's revenue comes from India.

Lyka Labs (BOM:500259) Headlines

No Headlines